Literature DB >> 10632734

Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.

E Santagostino1, P M Mannucci, A Bianchi Bonomi.   

Abstract

In the last years, the availability in Italy of technologically advanced products for replacement therapy has produced significant changes in the management of haemophilia and of hereditary bleeding disorders in general. With the aim of a uniform approach to treatment, the Italian Association of Haemophilia Centres express in these guidelines a consensus on therapeutic strategies designed to ensure the highest degree of safety and efficacy for the treatment of inherited coagulopathies. The guidelines provide specific recommendations for the choice of the product according to updated scientific evidence, and advice on optimal dosages for the treatment of rare bleeding disorders. The system for haemophilia care and funding in Italy is briefly described.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10632734     DOI： 10.1046/j.1365-2516.2000.00361.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  15 in total

Review 1.  Prothrombin complex concentrates: an update.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

Review 3.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Clinical use and the Italian demand for prothrombin complex concentrates.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Monica Lanzoni; Fabio Candura; Stefania Vaglio; Samantha Profili; Giuseppina Facco; Gabriele Calizzani; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

6.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

7.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 8.  Uncovered needs in the management of inherited bleeding disorders in Italy.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 9.  State of care for hemophilia in pediatric patients.

Authors:  Elena Santagostino; Alessandro Gringeri; Pier M Mannucci
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.